Literature DB >> 2019751

The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.

M C Steinhoff1, N A Halsey, L F Fries, M H Wilson, J King, B A Burns, R K Samorodin, V Perkis, B R Murphy, M L Clements.   

Abstract

Characteristics of avian-human (ah) and cold-adapted (ca) influenza A/Kawasaki/9/86 (H1N1) reassortant vaccine viruses were compared in 37 seronegative adults and 122 seronegative infants and children. The 50% human infectious dose (HID50) in infants and children was 10(2.9) and 10(2.6) TCID50 for the ah and ca vaccine, respectively. The ah influenza A/Kawasaki/9/86 reassortant was reactogenic: 24% of infants and children infected with greater than or equal to 100 HID50 had fever greater than or equal to 39.4 degrees C. Since H3N2 ah vaccines were previously shown to be adequately attenuated, it is reasonable to suggest that the genes that code for hemagglutinin and neuraminidase of the H1N1 virus apparently influence the reactogenicity of reassortant viruses derived from the avian influenza A/Mallard/New York/6750/78 donor virus. Because this avian virus does not reproducibly confer a satisfactory level of attenuation to each subtype of influenza A virus, it is not a suitable donor virus for attenuation of wild-type influenza viruses. In contrast, the ca A/Ann Arbor/6/60 donor virus reliably confers attenuation characteristics to a variety of H1N1 and H3N2 influenza A viruses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019751     DOI: 10.1093/infdis/163.5.1023

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity.

Authors:  T Watanabe; S Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.

Authors:  E L Anderson; F K Newman; H F Maassab; R B Belshe
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

3.  Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein.

Authors:  M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever.

Authors:  L F Fries; D M Waag; J C Williams
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

5.  Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.

Authors:  M L Clements; E K Subbarao; L F Fries; R A Karron; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 6.  Vaccines for preventing influenza in healthy children.

Authors:  Tom Jefferson; Alessandro Rivetti; Carlo Di Pietrantonj; Vittorio Demicheli; Eliana Ferroni
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children.

Authors:  M C Steinhoff; L F Fries; R A Karron; M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

8.  Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase.

Authors:  M R Castrucci; P Bilsel; Y Kawaoka
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  Biologic importance of neuraminidase stalk length in influenza A virus.

Authors:  M R Castrucci; Y Kawaoka
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  An avian live attenuated master backbone for potential use in epidemic and pandemic influenza vaccines.

Authors:  Danielle Hickman; Md Jaber Hossain; Haichen Song; Yonas Araya; Alicia Solórzano; Daniel R Perez
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.